CEO Derek Maetzold sold 32,346 shares (48.1% of holdings) across 3 transactions for $1,251,399.69
Derek Maetzold, President & Chief Executive Officer of Castle Biosciences, executed 3 separate sales totaling 32,346 shares for $1,251,399.69 on December 15–16, 2025, at prices ranging from $38.55 to $39.30. This disposition reduced his holdings from 67,215 shares to 34,869 shares, representing a 48.1% reduction in his post-transaction holdings. The sale occurred within the stock's 52-week range ($14.65–$39.95) and near its 52-week high of $39.95 (-0.7%), following a pronounced rally: 90-day change of +69.0% and 30-day change of +16.8%. The company's fundamentals show strong revenue growth (+51.1% year-over-year, with latest quarterly revenue of $83,043,000.00) but current losses (net income of $-501,000.00), and an elevated valuation multiple (P/E of 60.09). The magnitude of the reduction and the proximity to 52-week highs warrant investor review of the company's forward guidance and competitive positioning.